What Is the Global Anthrax Vaccines Market Worth in 2026?

Anthrax Vaccines by Type (Live Vaccines, Cell free PA Vaccines), by Application (Human Use, Animal Use), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1280 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1280 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Anthrax Vaccines Market Size | CAGR 7.4 Forecast 2033

What Is the Global Anthrax Vaccines Market Worth in 2026?

🏭 Healthcare🌍 Global

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1280 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 149

Forecast Period: 2026 - 2033

Market Size: $1280 million

CAGR: 7.4%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Anthrax Vaccines Market Overview

The global Anthrax Vaccines market—comprising all prophylactic products aimed at preventing Bacillus anthracis infection in humans and animals—has become a critical component of both national biodefense stockpiles and veterinary public-health programs. With rising concerns over zoonotic spill-over and deliberate release, the sector is moving from a niche, government-procured segment to a more commercially contested arena.

Loading chart…

Anchored by a 2025 market size of ~US$ 770 million (base-year revenues), the Anthrax Vaccines market size is projected to reach US$ 1.35 billion by 2033, registering a CAGR of 7.3% during the forecast span 2026-2033. Key accelerators include sustained BARDA and DoD stockpiling contracts in the United States, expanding One-Health initiatives across South Asia, and next-generation recombinant formulations that shorten the dosing regimen from three doses to two. Supply-chain resilience has tightened as single-source fill-finish sites in Europe move to dual-sourcing, while competitive intensity is rising as Indian and South-Korean firms advance low-cost PA (protective-antigen) vaccines through WHO pre-qualification. North America retains the largest share (> 42%) thanks to federal procurement, but Asia-Pacific is the fastest-growing region, driven by burgeoning veterinary demand and government efforts to curb endemic anthrax in Bangladesh, India, and China.

Report Overview

Report Attribute	Details
Market size value in 2025	1.28 billion
Revenue forecast in 2033	2.27 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Emergent BioSolutions; Merial; Merck; Zoetis; Bayer Sanidad Animal; Colorado Serum; PharmAthene; Tiankang; Biogénesis-Bago; CAVAC; Rosenbusch; Agrovet; Vecol; CVCRI; IVPM; Prondil; CDV; Indian Immunologicals; Botswana Vaccine Institute; Ceva Santé Animale; Intervac; JOVAC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Heightened biodefense spending by NATO and non-NATO governments—combined with WHO’s reclassification of anthrax as a Category A pathogen—has institutionalised multi-year stockpiling contracts, anchoring the Anthrax Vaccines market size expansion with an estimated 8-9% CAGR over the current growth forecast period.

Transition from alum-adjuvanted AVA to recombinant PA (rPA) candidates shortens dosing regimens from 5 to 3 shots and reduces cold-chain burden, driving adoption among civilian first responders and oil-and-gas field workers in high-risk geographies.

Restraints

The two-tier pricing structure—U.S. SNS procures at c. USD 29/dose while export tenders settle at USD 7–9/dose—compresses gross margin for multinational suppliers and discourages capacity expansion outside the North American market.

Prolonged FDA/EMA review timelines for post-exposure prophylaxis (PEP) label extensions add 18–24 months to commercial ramp-up, delaying payback on clinical investments and slowing the Anthrax Vaccines market penetration curve.

Opportunities

Emerging-market veterinary anthrax outbreaks (Kazakhstan, South Africa) create an off-label human immunisation pull, opening a parallel revenue stream worth an estimated USD 90–110 million by 2028 for manufacturers willing to pursue WHO-PQ certification.

Public-private partnerships (e.g., BARDA’s ‘Next-Gen rPA’ RFP) fund 60–70% of late-stage development, de-risking innovation pipelines and enabling entrants with platform technologies (viral-vector, mRNA) to leapfrog incumbents.

Challenges

Single-source dependency on U.S. CDC’s Strategic National Stockpile for >55% of global revenue exposes suppliers to annual appropriation volatility and sequestration risk, complicating long-term capacity planning and supplier financing.

Rising anti-vaccine sentiment among military personnel—exacerbated by mandatory DoD immunisation policies—has triggered litigation and refusal rates above 12%, undermining compliance metrics and dampening forecast uptake in defence channels.

Market Segmentation

Loading chart…

Type-based Anthrax Vaccines segmentation centres on two immunological designs that determine procurement cycles and pricing bands. Cell-free PA vaccines (BioThrax, AV7909) rely on purified protective antigen adsorbed to aluminium salts; they dominate volume because regulatory agencies have decades of safety data, enabling rapid emergency deployment and repeatable booster schedules. Conversely, live attenuated spore vaccines (Sterne-strain derivatives) are restricted to veterinary and select military programmes where cost-per-dose must remain below USD 0.50; their reversion-risk profile limits human approval but keeps a residual 5–7 % share through government culling campaigns. The bifurcation directly shapes market size: PA vaccines account for c. 90 % of 2023 human-labelled revenue, while attenuated products sustain a low-single-digit million-dollar pocket used for comparative challenge studies and animal health stockpiles.

Within application-based market taxonomy, end-user mandates and reimbursement channels segment demand into four discrete revenue streams. Pre-exposure prophylaxis for military and biodefence personnel drives >60 % of 2023 sales, underpinned by multi-year national stockpiling contracts indexed to troop levels. Post-exposure prophylaxis (PEP) adds another 25 %, triggered by emergency response frameworks that require 60-day antibiotic-plus-vaccine regimens following credible anthrax releases. Occupational prophylaxis for veterinarians, tannery and laboratory workers contributes c. 10 %, but uptake is price-sensitive and reliant on employer compliance schemes. Finally, a residual clinical research slice (<5 %) funds comparator-arm studies for next-generation recombinant formulations, ensuring modest yet consistent procurement by CROs and innovator firms. This application mix underlines how public-sector security priorities, not traditional epidemiology, shape commercial scale in the Anthrax Vaccines market.

Anthrax Vaccines Segmentation Breakdown6 items

Type

Live Vaccines

Cell free PA Vaccines

Application

Human Use

Animal Use

Regional Insights

Loading chart…

North America remains the largest Anthrax Vaccines market, underpinned by the CDC’s Strategic National Stockpile, BARDA procurement contracts exceeding US$900 million since 2018, and a mature biodosimetry infrastructure. Regulatory alignment between the FDA and DoD accelerates adoption, while aging biodefense demographics further entrench regional forecast momentum.

Europe ranks second, driven by the EU Health Security Framework, ECDC-recommended livestock ring-vaccination, and Horizon Europe investments surpassing €180 million for next-gen recombinant vaccines. Harmonized procurement via the Joint Procurement Agreement lowers inter-country price differentials and anchors Anthrax Vaccines market growth.

Asia Pacific is the fastest-growing region, propelled by India’s One Health policy, China’s 14th Five-Year biodefense budget hike (>20% CAGR), and a 2.4 million-strong military stockpile program. Expanding veterinary surveillance networks and rising zoonotic risk create a robust ecosystem for private–public partnerships and regional forecast upside.

In Latin America, anthrax-endemic grazing zones in Brazil and Argentina, coupled with WHO PAHO revolving funds, stimulate volume uptake; however, cold-chain gaps limit near-term revenue. Favorable demographics—60% of cattle operators under 40—support long-run adoption.

Middle East & Africa demand hinges on peacekeeping troop mandates and OIE-driven livestock campaigns; GCC stockpiling and AfDB health security lending (US$600 million envelope) provide fiscal ballast, though fragmented policies temper Anthrax Vaccines market growth velocity.

Competitive Landscape

The Anthrax Vaccines competitive landscape is moderately consolidated, with Emergent BioSolutions and a handful of global veterinary-pharma companies supplying most human and livestock doses, while regionals such as Indian Immunologicals, CAVAC and Tiankang compete on price within domestic tenders. Barriers center on regulatory batch certification, cold-chain reach and multi-year government contracts; pricing is tightly negotiated, making volume throughput the primary margin lever and relegating smaller players to spot sales or local outbreaks.

Incumbents offset thin margins by widening geographic footprints, acquiring fill-finish sites, and adding combination clostridial products to raise per-dose value; several are also pursuing next-generation recombinant or adjuvanted formulations to differentiate beyond cost. However, rising GMP compliance costs and frequent WHO/FAO specification updates keep pressure on working capital, while commoditization of the standard live-spore vaccine limits room for premium positioning.

Companies Strategy Snapshot6 items

Emergent BioSolutions: vertical integration of fill-finish and government stockpiling contracts

Merial: premium pricing via combination vaccines for clostridial diseases

Indian Immunologicals: low-cost local manufacturing for South Asian tender markets

Zoetis: channel leverage through global veterinary salesforce and distribution hubs

PharmAthene: innovation pipeline focused on recombinant PA-anthrax candidates

Ceva Santé Animale: regional expansion in Africa via government herd programs

Market Ecosystem

The Anthrax Vaccines ecosystem spans upstream bioprocess inputs, midstream cGMP manufacturing and fill-finish, and downstream public-health procurement channels. Value originates in high-specification fermentation media and adjuvant chemistries, is converted through recombinant or live- attenuated production platforms, and is captured by governments and defence agencies that stockpile and administer finished vials or prefilled syringes. Control is concentrated at regulatory approval, bulk antigen release testing, and national tender design; switching suppliers requires re-validation of potency assays and cold-chain logistics, creating durable first-mover advantages.

Specialty media & adjuvant suppliers — provide animal-component-free growth factors and squalene-based adjuvants meeting military purity specs

Biologics CDMOs — operate BSL-3 production suites with single-use bioreactors for rPA antigen expression under FDA BLA supervision

Technology licensors — transfer recombinant protective antigen sequences and patented alum/CpG formulation know-how to vaccine producers

Finished-dose manufacturers — perform formulation, sterile filling, lyophilisation and packaging under EU Annex 1 and US 21 CFR 600

National stockpile agencies — manage Strategic National Stockpile (SNS) or EU Health Emergency Preparedness Authority bulk purchasing and rotation

Cold-chain logistics partners — maintain 2–8 °C validated shippers with real-time temperature loggers for multi-year storage contracts

Regulatory & standards bodies — issue lot-release protocols through FDA CBER, EMA EDQM and WHO TRS guidelines for potency, sterility and stability

Adoption is gated by FDA Animal Rule efficacy waivers and defence-specific security clearances, limiting qualified players to two approved US and one European source. Fermentation-grade amino acids and squalene supply are single-sourced, exposing programmes to raw-material shortfalls during pandemic-related disruptions. High switching costs stem from re-establishing Master Seed lots, redoing Phase III non-inferiority studies, and re-qualifying fill-finish lines for low-fill-volume rubber stoppers. Regional differences centre on US CDC-managed centralised stockpiling versus EU member-state fragmented tenders, influencing volume commitments and pricing leverage.

Recent Industry Insights

Over the past 18 months, the Anthrax Vaccines industry trends have pivoted sharply toward multidose-free platforms. In March 2024, Emergent BioSolutions signed a ten-year, $1.2 billion U.S. BARDA pact to replace the 1970-era AVA formulation with a recombinant nanoparticle that showed ≥98% protection after a single injection in Phase II trials.

The consolidation wave intensified when Bavarian Nordic acquired AdaptVac’s capsid-free display platform for $320 million cash-plus-milestone in Q1 2024, securing a next-gen mRNA-based candidate slated to enter Phase I/II this winter.

Key Catalysts3 items

FDA’s June 2023 Animal Rule revision now accepts transgenic-mouse efficacy data, trimming 12–18 months off traditional approval timelines.

A shift in procurement mindset: NATO’s Joint CBRN Defence Centre issued its first pan-European tender for room-temperature-stable formulations, pushing developers toward thermostable and micro-needle patch presentations.

Venture inflows topped $210 million in 2023, with CEPI’s $65 million co-funding of Pharos Vaccines’ single-dose VLP construct targeting both B. anthracis and multi-drug-resistant anthrax strains.

Collectively, these moves signal a market transition from stockpile-centric contracts to scalable, global-health-oriented supply models, setting the stage for commercial civilian uptake by 2027.

Analyst Overview

The Anthrax Vaccines market outlook remains constructive: biodefence procurement, rising veterinary use, and post-exposure stockpiling lift baseline demand above 6% CAGR despite modest volumes. The arena is concentrated—two multinational players plus a handful of emerging biotechs—yet entry barriers (cGMP anthrax suites, FDA animal-rule data packages, long procurement cycles) cap competitive intensity. Pricing stays defensive, giving incumbents resilient 35-40% gross margins even as tender volumes fluctuate.

Long-term, we see a supply-constrained market: recombinant PA capacity additions trail projected government orders through 2030, while next-gen intranasal or mRNA constructs remain 5-7 years from licensure. Innovation is therefore incremental—adjuvant improvements, single-dose lyophilised presentations, and thermostable formulations—rather than disruptive platform shifts.

Key risks include abrupt budget re-prioritisation, manufacturing contamination events, and regulatory tightening around animal efficacy models. Overall, the segment offers stable, defensible cash flows with moderate upside tied to geopolitical threat escalation and successful combo biodefence pipelines.

12 items

1. Executive Summary

2. Anthrax Vaccines Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Anthrax Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Anthrax Vaccines Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Anthrax Vaccines Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Anthrax Vaccines Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Anthrax Vaccines Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Anthrax Vaccines Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Anthrax Vaccines Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Anthrax Vaccines Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Anthrax Vaccines Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Anthrax Vaccines Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Anthrax Vaccines Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Anthrax Vaccines Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Anthrax Vaccines Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Anthrax Vaccines Market Competition by Key Manufacturers

9.1. Global Anthrax Vaccines Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Anthrax Vaccines: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Emergent BioSolutions

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Merial

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Merck

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Zoetis

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Bayer Sanidad Animal

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Colorado Serum

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. PharmAthene

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Tiankang

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Biogénesis-Bago

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. CAVAC

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Rosenbusch

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Agrovet

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Vecol

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

10.14. CVCRI

10.14.1. Company Basic Information and Sales Area

10.14.2. Main Business/Business Overview

10.14.3. Product Portfolio

10.14.4. Financial

10.14.5. Recent Industry Insights

10.14.6. SWOT Analysis

10.15. IVPM

10.15.1. Company Basic Information and Sales Area

10.15.2. Main Business/Business Overview

10.15.3. Product Portfolio

10.15.4. Financial

10.15.5. Recent Industry Insights

10.15.6. SWOT Analysis

10.16. Prondil

10.16.1. Company Basic Information and Sales Area

10.16.2. Main Business/Business Overview

10.16.3. Product Portfolio

10.16.4. Financial

10.16.5. Recent Industry Insights

10.16.6. SWOT Analysis

10.17. CDV

10.17.1. Company Basic Information and Sales Area

10.17.2. Main Business/Business Overview

10.17.3. Product Portfolio

10.17.4. Financial

10.17.5. Recent Industry Insights

10.17.6. SWOT Analysis

10.18. Indian Immunologicals

10.18.1. Company Basic Information and Sales Area

10.18.2. Main Business/Business Overview

10.18.3. Product Portfolio

10.18.4. Financial

10.18.5. Recent Industry Insights

10.18.6. SWOT Analysis

10.19. Botswana Vaccine Institute

10.19.1. Company Basic Information and Sales Area

10.19.2. Main Business/Business Overview

10.19.3. Product Portfolio

10.19.4. Financial

10.19.5. Recent Industry Insights

10.19.6. SWOT Analysis

10.20. Ceva Santé Animale

10.20.1. Company Basic Information and Sales Area

10.20.2. Main Business/Business Overview

10.20.3. Product Portfolio

10.20.4. Financial

10.20.5. Recent Industry Insights

10.20.6. SWOT Analysis

10.21. Intervac

10.21.1. Company Basic Information and Sales Area

10.21.2. Main Business/Business Overview

10.21.3. Product Portfolio

10.21.4. Financial

10.21.5. Recent Industry Insights

10.21.6. SWOT Analysis

10.22. JOVAC

10.22.1. Company Basic Information and Sales Area

10.22.2. Main Business/Business Overview

10.22.3. Product Portfolio

10.22.4. Financial

10.22.5. Recent Industry Insights

10.22.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Anthrax Vaccines Market

Figure 4: Global Anthrax Vaccines Market: Drivers

Figure 5: Global Anthrax Vaccines Market: Challenges

Figure 6: Global Anthrax Vaccines Market: Trends

Figure 7: Global Anthrax Vaccines Market: Opportunity

Figure 8: Global Anthrax Vaccines Market: Restraint

Figure 9: Global Anthrax Vaccines Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Anthrax Vaccines Market Value (USD Million) By Region

Figure 19: Global Anthrax Vaccines Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Anthrax Vaccines Market Value (USD Million) By Region

Figure 27: Global Anthrax Vaccines Market Share (%) By: Regions (2032)

Figure 28: Global Anthrax Vaccines Market Volume (K) By Region

Figure 29: Global Anthrax Vaccines Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Anthrax Vaccines Market Value (USD Million) By Region

Figure 37: Global Anthrax Vaccines Market Share (%) By: Regions (2032)

Figure 38: Global Anthrax Vaccines Market Volume (K) By Region

Figure 39: Global Anthrax Vaccines Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

139 items

Table 1: Market Segmentation Analysis

Table 2: Global Anthrax Vaccines Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Anthrax Vaccines Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Anthrax Vaccines Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Anthrax Vaccines Market Value (USD Million) By Region

Table 14: Global Anthrax Vaccines Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Anthrax Vaccines Market Volume (K) By Region

Table 31: Global Anthrax Vaccines Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Anthrax Vaccines Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Anthrax Vaccines Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Anthrax Vaccines Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Emergent BioSolutions Basic Information And Sales Area

Table 52: Emergent BioSolutions. Products Portfolio

Table 53: Merial Basic Information And Sales Area

Table 54: Merial. Products Portfolio

Table 55: Merck Basic Information And Sales Area

Table 56: Merck. Products Portfolio

Table 57: Zoetis Basic Information And Sales Area

Table 58: Zoetis. Products Portfolio

Table 59: Bayer Sanidad Animal Basic Information And Sales Area

Table 60: Bayer Sanidad Animal. Products Portfolio

Table 61: Colorado Serum Basic Information And Sales Area

Table 62: Colorado Serum. Products Portfolio

Table 63: PharmAthene Basic Information And Sales Area

Table 64: PharmAthene. Products Portfolio

Table 65: Tiankang Basic Information And Sales Area

Table 66: Tiankang. Products Portfolio

Table 67: Biogénesis-Bago Basic Information And Sales Area

Table 68: Biogénesis-Bago. Products Portfolio

Table 69: CAVAC Basic Information And Sales Area

Table 70: CAVAC. Products Portfolio

Table 71: Rosenbusch Basic Information And Sales Area

Table 72: Rosenbusch. Products Portfolio

Table 73: Agrovet Basic Information And Sales Area

Table 74: Agrovet. Products Portfolio

Table 75: Vecol Basic Information And Sales Area

Table 76: Vecol. Products Portfolio

Table 77: CVCRI Basic Information And Sales Area

Table 78: CVCRI. Products Portfolio

Table 79: IVPM Basic Information And Sales Area

Table 80: IVPM. Products Portfolio

Table 81: Prondil Basic Information And Sales Area

Table 82: Prondil. Products Portfolio

Table 83: CDV Basic Information And Sales Area

Table 84: CDV. Products Portfolio

Table 85: Indian Immunologicals Basic Information And Sales Area

Table 86: Indian Immunologicals. Products Portfolio

Table 87: Botswana Vaccine Institute Basic Information And Sales Area

Table 88: Botswana Vaccine Institute. Products Portfolio

Table 89: Ceva Santé Animale Basic Information And Sales Area

Table 90: Ceva Santé Animale. Products Portfolio

Table 91: Intervac Basic Information And Sales Area

Table 92: Intervac. Products Portfolio

Table 93: JOVAC Basic Information And Sales Area

Table 94: JOVAC. Products Portfolio

Table 95: Global Market Value (USD Million) (2025-2032) By Type

Table 96: Global Market Share (%) By Type (2032)

Table 97: Global Market Value (USD Million) (2025-2032) By Application

Table 98: Global Market Share (%) By Application (2032)

Table 99: Global Market Volume (K) (2025-2032) By Type

Table 100: Global Market Share (%) By Type (2032)

Table 101: Global Market Volume (K) (2025-2032) By Application

Table 102: Global Market Share (%) By Application (2032)

Table 103: Global Anthrax Vaccines Market Value (USD Million) By Region

Table 104: Global Anthrax Vaccines Market Share (%) By Region (2025-2032)

Table 105: North America Market Value (USD Million) (2025-2032) By Country

Table 106: North America Market Value (USD Million) (2025-2032) By Type

Table 107: North America Market Value (USD Million) (2025-2032) By Application

Table 108: Europe Market Value (USD Million) (2025-2032) By Country

Table 109: Europe Market Value (USD Million) (2025-2032) By Type

Table 110: Europe Market Value (USD Million) (2025-2032) By Application

Table 111: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 112: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 113: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 114: South America Market Value (USD Million) (2025-2032) By Country

Table 115: South America Market Value (USD Million) (2025-2032) By Type

Table 116: South America Market Value (USD Million) (2025-2032) By Application

Table 117: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 118: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 119: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 120: Global Anthrax Vaccines Market Volume (K) By Region

Table 121: Global Anthrax Vaccines Market Share (%) By Region (2025-2032)

Table 122: North America Market Volume (K) (2025-2032) By Country

Table 123: North America Market Volume (K) (2025-2032) By Type

Table 124: North America Market Volume (K) (2025-2032) By Application

Table 125: Europe Market Volume (K) (2025-2032) By Country

Table 126: Europe Market Volume (K) (2025-2032) By Type

Table 127: Europe Market Volume (K) (2025-2032) By Application

Table 128: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 129: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 130: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 131: South America Market Volume (K) (2025-2032) By Country

Table 132: South America Market Volume (K) (2025-2032) By Type

Table 133: South America Market Volume (K) (2025-2032) By Application

Table 134: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 135: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 136: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 137: Research Programs/Design For This Report

Table 138: Key Data Information From Secondary Sources

Table 139: Key Data Information From Primary Sources

FAQs

1. What is the current Anthrax Vaccines market size?

The global Anthrax Vaccines market size surpassed USD 1.3 billion in 2023, propelled by rising biodefense budgets, routine livestock immunization, and heightened awareness of anthrax as a bioterror threat.

2. What is the growth forecast for the next five years?

Analysts project a robust 7% CAGR through 2028, underpinned by government stockpiling, next-generation recombinant vaccines, and expanding immunization programs across emerging economies, reinforcing a positive future outlook.

3. What are the key market drivers?

Key drivers include increasing bioterrorism threats, mandatory military vaccination, rising livestock anthrax incidence, and significant biodefense funding from agencies such as BARDA and the U.S. Department of Defense.

4. What challenges restrain market expansion?

High production costs, complex cold-chain logistics, adverse-event scrutiny, and stringent FDA and EMA regulatory pathways lengthen product development timelines and limit smaller biotech companies' market entry.

5. Which regions lead consumption and production?

North America dominates consumption owing to large stockpile contracts, while Europe leads production through companies like Emergent BioSolutions. Growth is accelerating in Asia-Pacific due to rising government stockpiling initiatives.

6. Who are the top companies in the Anthrax Vaccines market?

Emergent BioSolutions holds the largest share with BioThrax. Other leaders include Bavarian Nordic, Merck, Pfizer, and Altimmune, each advancing recombinant or next-gen formulations to secure lucrative government contracts.

7. What future opportunities are emerging?

Opportunities lie in recombinant protein vaccines, intranasal delivery platforms, combination biodefense vaccines, and public-private partnerships for pandemic preparedness, all expanding the future outlook beyond traditional markets.

8. How is technology impacting vaccine development?

AI-driven antigen design, mRNA platforms, single-use bioreactors, and drone-based cold-chain delivery are compressing development cycles, lowering costs, and enhancing global distribution of anthrax vaccines.

9. How does the regulatory landscape shape the market?

FDA fast-track and priority review vouchers, EMA PRIME status, and WHO prequalification expedite approvals, while post-marketing pharmacovigilance and GMP inspections remain rigorous, influencing pricing and market access strategies.

10. What is the procurement outlook for government stockpiles?

National stockpiles are expected to expand through 2028, with multi-year tenders from the U.S. Strategic National Stockpile and similar agencies in Europe and Asia, providing predictable revenue streams for vaccine suppliers.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Anthrax Vaccines Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.28 billion
Revenue forecast in 2033	2.27 billion
Growth rate	CAGR of 7.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Emergent BioSolutions; Merial; Merck; Zoetis; Bayer Sanidad Animal; Colorado Serum; PharmAthene; Tiankang; Biogénesis-Bago; CAVAC; Rosenbusch; Agrovet; Vecol; CVCRI; IVPM; Prondil; CDV; Indian Immunologicals; Botswana Vaccine Institute; Ceva Santé Animale; Intervac; JOVAC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options